-
.
- Raymond James has actually updated Dyne Therapies Inc DYN from Outperform to Solid Buy as well as elevated the cost target to $27 from $16.
- .(* )The ACHIEVE Stage 1/2 test reviewing DYNE-101 for DM1 is underway. It consists of a 24-week several rising dosage (MAD), a 24-week open-label expansion, as well as a 96-week long-lasting expansion.
- .
- Avidity Biosciences Inc RNA, which need to function as a tailwind for DYN in 2023 in between currently as well as information (specifically since the expert assumes RNA will certainly relocate greater additionally). . Connected:
- . DYNE-101 will certainly be an important restorative if first reduced dosages just recapitulate the MARINA acting information account without the SAE. .
- .(* )DM1 is, at its optimal, a ~$ 9 billion income possibility composes Raymond James expert, which Dyne as well as Avidity will certainly complete.
- Rate Activity:(* )DYN shares are up 10.3% at $12.79 on the last check Monday.
- © 2023 Benzinga.com. Benzinga does not supply financial investment suggestions. All legal rights scheduled.
- .
.(* )The expert keeps in mind distance to myotonic dystrophy kind 1 (DM1) information for DYNE-101 (2H23), for which it has high sentence, will certainly declare.
.(* )The ACHIEVE test, developed to be registrational, is anticipated to sign up about 64 grown-up clients. Information from the MAD placebo-controlled part of the ACHIEVE test on security, tolerability, as well as splicing are expected in the 2nd fifty percent of 2023.
Raymond James
additionally sees a considerable evaluation void with
Avidity Biosciences Or Dyne Therapies – Keep Reading Raymond James’ Score Skew
Raymond James literary works evaluation drives traditional assumptions on spliceopathy.
.
.
Uploaded In:
